Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society

Maturitas ◽  
2014 ◽  
Vol 79 (3) ◽  
pp. 349-354 ◽  
Author(s):  
D.J. Portman ◽  
M.L.S. Gass
Keyword(s):  
Sexual Health ◽  
International Society ◽  
North American ◽  
Genitourinary Syndrome Of Menopause ◽  
Vulvovaginal Atrophy ◽  
The North ◽  
Women’S Sexual Health ◽  
Genitourinary Syndrome

scholarly journals An Update of the North American Chapter of the International Society of Pharmacovigilance (NASoP)

Drug Safety ◽  
2021 ◽  
Author(s):  
Maxine Gossell-Williams ◽  
Veronique F. Kugener ◽  
Maribel Salas ◽  
Kenneth I. Maynard ◽  
Abimbola Cole
Keyword(s):  
International Society ◽  
North American ◽  
North American Chapter ◽  
The North

Non-hormonal treatment for genitourinary syndrome of menopause

2021 ◽  
Vol 20 (2) ◽  
pp. 141-146
Author(s):  
N.A. Tatarova ◽  
◽  
V.A. Linde ◽  
S.N. Gusev ◽  
◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hormonal Treatment ◽  
Therapeutic Effects ◽  
Life Questionnaire ◽  
Genitourinary Syndrome Of Menopause ◽  
Quality Of Life Questionnaire ◽  
Vulvovaginal Atrophy ◽  
Positive Effects ◽  
Genitourinary Syndrome

The genitourinary syndrome of menopause (GSM) is due to the development of atrophic and dystrophic processes in estrogendependent tissues and structures of the lower third of urinary tract in different periods of aging of the reproductive system. Nonhormonal treatment for GSM is considered as a first-line treatment and includes the use of gels, creams and suppositories that contribute to the restoration of hydrolipid balance, stimulating the collagen production that have an anti-inflammatory, antiseptic, regenerating effect, as well as increasing mucosal resistance and reducing the risk of adhesion of conditionally pathogenic infection. Objective. To evaluate the effectiveness, safety and acceptability of the vaginal cream for intimate hygiene EstrogialTM Plus in women with symptoms of vulvovaginal atrophy (VVA) and GSM. Patients and methods. 24 women aged 43 to 58 were examined. The inclusion criteria were the symptoms of GSM and VVA, the vaginal health index – no more than 20 points. During the course of the study, four visits were carried out, including standard observational procedures, filling the Quality of Life Questionnaire, the administration of treatment. The application of the cream Estrogial™ Plus in doses was prescribed 1 time per day on the vulvar vestibule for 30 days. The effectiveness of therapy was evaluated, all patients continued therapy for up to 60 days. According to the modified questionnaire for general clinical assessment, the state «very much improved» was revealed in 83.3% of patients with a severe form of GSM and VVA and in 66.7% with moderate VVA, «much improved» – in the rest. After treatment, 52% of patients had no symptoms of VVA, and 48% had symptoms in a mild form. Filling the Menopause-Specific Quality of Life Questionnaire (MENQOL), all 24 patients reported positive effects in the form of increased libido and reduced vaginal dryness during sexual intercourses. The study presents clinical cases of cured patients with GSM and VVA. Conclusion. The data obtained during the study make it possible to conclude that the intravaginal administration of the cream EstrogialTM Plus in doses is effective for the treatment of GSM and VVA. The proven therapeutic effects and safety of the use of local non-hormonal treatment enhance the prospects for providing treatment and preventive care for women during the menopausal transition and menopause. Key words: vulvovaginal atrophy, genitourinary syndrome of menopause, non-hormonal treatment, Estrogial™ Plus

Sign in / Sign up

Export Citation Format

Share Document